

Big Money, Rare Jury Reversal: Gilead's \$2.54B Victory Over Merck

February 23, 2018

ATTORNEYS

Landmon, Chad

PRACTICE AREAS

Intellectual Property

Greg Langlois

Bloomberg BNA Pharmaceutical & Life Sciences News

Axinn partner Chad Landmon was quoted in the *Bloomberg BNA Pharmaceutical & Life Sciences News* article, "Big Money, Rare Jury

Reversal: Gilead's \$2.54B Victory Over Merck."

Click here to access the article. A subscription is required.

